Experience

NanoString Technologies, Inc.

• United States
• Biotechnology Research
• 500 - 600 Employee

• Scientist

  • Feb 2016 - Present

  Dec 2019 - present: Member of the Product Development team focused on the support and expansion of the NanoString GeoMx DSP technology including the execution of validation studies for new GeoMx reagents and readout capabilities and the transfer of formulation and functional QC testing methods from Development to Manufacturing. Feb 2016- Dec 2019: Diagnostic Development team member focused on the analytical validation of two Diagnostic IVD Gene Expression Assays on the nCounter platform in support of global regulatory submissions. Prepared Study Plans/Protocols according to CLSI and ISO guidance documents, executed multiple Verification and Validation (V&V) studies, reviewed study data, worked with BioStats team on final data analysis and prepared Study Reports with review and approval of Quality and Regulatory teams. Prepared a Manufacturing Process Validation Protocol and the Manufacturing PV Study Report. Recipient of a 2018 NanoString Key Corporate Goals Award for LymphMark Clinical Assay Development for "Best Team Player/Contributor" Show less



Oncofactor Corporation

• United States
• Biotechnology

• Senior Research Associate

  • Mar 2013 - 2015

  Oncofactor is developing immune-oncology therapeutics that specifically inhibit novel immune regulators expressed by tumors. The company identified and validated targets, generated therapeutic antibodies against those targets and characterized the antibodies in-vitro and in-vivo. My responsibilities included participation in the design and execution of PK and PD models, monitoring the growth of subcutaneous syngeneic tumors with calipers and in-vivo imaging, treated mice with therapeutic antibody IP, harvesting of blood by cardiac puncture and tissue for ex-vivo analysis, analysis of the tumor model data, analysis of tissue RNA by qRT-PCR . I presented data at weekly lab meetings and assisted in the preparation of data slides for Scientific Advisory meetings and Board of Director meetings. Show less



Groove Biopharma

• Seattle WA

• Senior Research Associate

  • 2008 - 2013

  Groove focused on evaluating novel microRNA therapeutics for disease indication including oncology, fibrosis and hematopoiesis. My responsibilities included transfer of materials, methods and samples to and from CROs, coordination of sample processing and inventories, development and optimization of cell based assays, evaluation of different modifications on the function of the microRNA inhibitors in-vitro and in-vivo, development of methodology of detection of the inhibitors from in-vivo samples, analysis of tissue RNA samples by qRT-PCR for microRNAs and downstream targets, presented results to the company and assisted in the preparation of data to be presented to the Board of Directors. Show less



Recodagen Corporation

• United States
• Biotechnology Research

• Senior Research Associate

  • 2008 - 2008



ICOS

• Biotechnology Research
• 1 - 100 Employee

• Technical Scientist

  • 1990 - 2007

  While at ICOS I worked in several groups on many projects. I designed and developed anti-sense probes and controls for my use in RNAse protection assays to help determine the relative quantities of PDE isoforms. I contributed to two manuscripts on this work. I developed and performed nucleotide exchange assays for two different pairs of exchange factors. I contributed to two manuscripts on this work. I performed a cell based screen of a small molecule library for inhibitors of the complement cascade. I developed expression and purification protocols for Factor B and C2 I domain expression. And I contributed to a manuscript on Factor B (Structure, vol.12, 371- 378, 2004). I utilized site-directed mutagenesis to define the 1 I-domain allosteric site (IDAS) of VLA1. I evaluated the effects of mutations on VLA1 function. I generated point mutations in CD11a, CD11b, alpha E and alpha D to confirm the presence of an IDAS in other integrins. I developed, optimized and performed cell adhesion assays for the VLA1 program. I developed conditions for culturing primary hepatic stellate cells (HSCs). I optimized collagen gel contraction assays using the HSCs. I developed a protocol for the large scale purification of neutrophils from human blood for use in cell-based screening of small molecules. I coordinated the effort of a small cell biology team and prepared weekly progress reports for the project team leader. I contributed to two manuscripts on this work. I was choosen as 1 of 6 individuals to be trained in the Dyax Corp. phage display technology. I successfully executed a phage display campaigns for an oncology cell surface target and a secreted protein target. I was the recipient of an Icosahedron Award for this work. Show less



Fred Hutch

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Associate

  • 1986 - 1990

  Research Associate in the lab of Dr. Richard E. Gelinas. Research Associate in the lab of Dr. Richard E. Gelinas.



Whitehead Institute

• United States
• Research Services
• 200 - 300 Employee

• Research Associate

  • 1984 - 1986

  Research Associate in the lab of Dr. Richard C. Mulligan. Research Associate in the lab of Dr. Richard C. Mulligan.



The Rockefeller University

• United States
• Research
• 700 & Above Employee

• Research Associate

  • 1982 - 1984

  Research Associate in the lab of Dr. Robert G. Roeder. Worked focused on the purification of transcription factors from primary tissues and HeLa cells. Research Associate in the lab of Dr. Robert G. Roeder. Worked focused on the purification of transcription factors from primary tissues and HeLa cells.